|
UNITED STATES |
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of April 2019
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☑
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☑
INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On April 5, 2019, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
On April 5, 2019, Mesoblast Limited submitted a Final Director’s Interest Notice to the Australian Securities Exchange, a copy of which is attached to this report as Exhibit 99.2.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.
|
|
|
|
|
|
|
|
|
Mesoblast Limited |
|
|
|
|
|
/s/ Charlie Harrison |
|
|
|
|
|
|
|
|
|
|
|
Charlie Harrison |
|
|
|
|
|
Company Secretary
|
|
|
Dated: April 10, 2019
|
Item |
|
|
|
|
|
|
|
99.1 99.2 |
|
Press release of Mesoblast Ltd, dated April 5, 2019. Final Director’s Interest Notice, Brian Jamieson.
. |
Exhibit 99.1
|
|
|
|
MESOBLAST TO PRESENT AT UPCOMING GLOBAL LIFE SCIENCE CONFERENCE IN LONDON
New York, USA; and Melbourne, Australia; April 5, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate presentation by the company at the H.C. Wainwright Global Life Sciences 2019 conference being held in London. The presentation is scheduled for Monday, April 8, 2019 at 11:50am GMT.
About Mesoblast
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) has leveraged its proprietary technology platform to establish a broad portfolio of late-stage allogeneic (off-the-shelf) product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
For further information, please contact:
Julie Meldrum Schond Greenway
Corporate Communications Investor Relations
T: +61 3 9639 6036 T: +1 212 880 2060
E: julie.meldrum@mesoblast.com E: schond.greenway@mesoblast.com
|
|
Mesoblast Limited
www.mesoblast.com |
Corporate Headquarters Level 38 55 Collins Street Melbourne 3000 Victoria Australia
T +61 3 9639 6036 F +61 3 9639 6030 |
United States Operations 505 Fifth Avenue Third Floor New York, NY 10017 USA
T +1 212 880 2060 F +1 212 880 2061 |
Asia 20 Biopolis Way #05-01 Centros Biopreneur 3 SINGAPORE 138668
T +65 6570 0635 F +65 6570 0176 |
|
|
|
|
|
|
|
|
|
|
Exhibit 99.2
Appendix 3Z
Final Director’s Interest Notice
Rule 3.19A.3
Appendix 3Z
Final Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001
|
Name of entity Mesoblast Limited |
|
ABN 68 109 431 870 |
We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.
|
Name of Director |
Brian Jamieson |
|
Date of last notice |
8 January 2019 |
|
Date that director ceased to be director |
31 March 2019 |
Part 1 - Director’s relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
|
Number & class of securities
(1) 150,000 options held directly; and (2) 75,000 shares held directly. |
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Z Page 1
Appendix 3Z
Initial Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered holder
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.
|
Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.
|
Number & class of Securities
570,000 shares held indirectly
|
Part 3 – Director’s interests in contracts
|
Detail of contract |
Not applicable |
|
Nature of interest |
Not applicable |
|
Name of registered holder (if issued securities)
|
Not applicable |
|
No. and class of securities to which interest relates |
Not applicable |
+ See chapter 19 for defined terms.
11/03/2002 Appendix 3Z Page 2